过去一年中添加的文章，按日期排序
Efficacy and safety of multikinase inhibitors for patients with refractory thyroid cancer: Systematic review and network meta-analysis
R Jing, N Wu, Y Wu, Q Zhang, Q Liang… - The Journal of …, 2024 - academic.oup.com
6 天前 - … aims to compare the efficacy of MKIs in improving 13 survival outcomes and
safety. 14 … Therefore, the efficacy and safety 2 of anlotinib on the patients with these patients …
safety. 14 … Therefore, the efficacy and safety 2 of anlotinib on the patients with these patients …
[HTML][HTML] Maintenance therapy with anlotinib after induction therapy with platinum-based chemotherapy for advanced non-small-cell lung cancer: A pooled analysis of 2 …
Y Liu, L Miao, X Chen, X Zhu, Y Li, J He, P Chen, S Dai… - Medicine, 2024 - journals.lww.com
6 天前 - … Anlotinib is effective, tolerable, and convenient in administration as a third-line …
This study aimed to evaluate the efficacy and safety of maintenance therapy with anlotinib after …
This study aimed to evaluate the efficacy and safety of maintenance therapy with anlotinib after …
Immunotherapy combined with antiangiogenic therapy as third‐or further‐line therapy for stage IV non‐small cell lung cancer patients with ECOG performance status …
S Li, ZS Yu, HZ Liu, SJ Li, MY Wang, FL Ning… - Cancer …, 2024 - Wiley Online Library
29 天前 - … ICI in combination with anlotinib was well-tolerated and showed clinical efficacy as
first-… Nevertheless, the efficacy and safety of this combination strategy as later-line therapy in …
first-… Nevertheless, the efficacy and safety of this combination strategy as later-line therapy in …
Efficacy and Safety of Anlotinib in Advanced Rhabdomyosarcoma: A Retrospective Study
T Wang, F Yan, F Lin - 2024 - researchsquare.com
30 天前 - … of anlotinib in this study was generally consistent with previous experiences in phase
I studies and safety … The safety and tolerability of anlotinib treatment were consistent with …
I studies and safety … The safety and tolerability of anlotinib treatment were consistent with …
Safety and efficacy of multi-target TKI combined with nivolumab in check-point inhibitor-refractory patients with advanced NSCLC: a prospective, single-arm, two-stage …
B Zhang, H Liu, C Shi, Z Gao, R Zhong, A Gu, T Chu… - BMC cancer, 2024 - Springer
31 天前 - … The safety and efficacy of this combination in NSCLC patients of other ethnicities …
full-dose anlotinib combined with nivolumab shows manageable safety and promising efficacy …
full-dose anlotinib combined with nivolumab shows manageable safety and promising efficacy …
Comparison of the efficacy and safety of different dose anlotinib in combination with immune checkpoint inhibitors for patients with advanced non-small cell lung …
T Tan, S Yuan, W Chu, J Jiang, M Chen, Q Xia, J Wang - 2024 - researchsquare.com
34 天前 - … dose anlotinib as second-line or later line therapy. Subsequently, the efficacy and
safety of the combination therapy as well as subgroup analyses of different doses of anlotinib …
safety of the combination therapy as well as subgroup analyses of different doses of anlotinib …
First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel/gemcitabine (PAAG) in metastatic pancreatic cancer: a …
H Sha, F Tong, J Ni, Y Sun, Y Zhu, L Qi, X Li… - … and Targeted Therapy, 2024 - nature.com
35 天前 - … Herein, we conducted a prospective, multicentre, single-arm, phase II trial
evaluating the efficacy and safety of penpulimab and anlotinib in combination with nab-paclitaxel/…
evaluating the efficacy and safety of penpulimab and anlotinib in combination with nab-paclitaxel/…
Efficacy and safety analysis of anlotinib in combination with immune checkpoint inhibitors for second-line and subsequent extensive-stage small-cell lung cancer
X Ying, Z Shi, R Shao, G You, Z Song - Neoplasma, 2024 - pubmed.ncbi.nlm.nih.gov
42 天前 - … on assessing the efficacy and safety of anlotinib in … -stage SCLC who received
anlotinib in combination with ICIs as … Combining anlotinib with immune checkpoint inhibitors …
anlotinib in combination with ICIs as … Combining anlotinib with immune checkpoint inhibitors …
Anlotinib combined with sintilimab as first-line treatment in patients with advanced non-clear cell renal cell carcinoma (nccRR): Preliminary results from an exploratory …
P Dong, W Wei, L Jiang, Z Zhang, D Wang, Y Peng… - 2024 - ascopubs.org
43 天前 - … Neither unexpected safety signals nor treatment-related death occurred. Conclusions:
Our results showed promising efficacy and acceptable toxicity of anlotinib plus sintilimab …
Our results showed promising efficacy and acceptable toxicity of anlotinib plus sintilimab …
Updated results from a phase II study of penpulimab plus anlotinib as first-line therapy in metastatic urothelial cancer (mUC).
B Yang, Q Xiong, Q Song, Y Long, G Guo, H Li - 2024 - ascopubs.org
43 天前 - … anlotinib have good efficacy and safety in multiple solid tumors. This study aimed
to evaluate the efficacy and safety of penpulimab plus anlotinib … on day 1 and anlotinib 8 mg …
to evaluate the efficacy and safety of penpulimab plus anlotinib … on day 1 and anlotinib 8 mg …
相关搜索
- efficacy and safety anlotinib in combination
- efficacy and safety cell lung cancer
- real world efficacy and safety
- efficacy and safety retrospective study
- retrospective review of efficacy and safety
- safety of anlotinib phase iib trial
- safety of anlotinib retrospective analysis
- efficacy of anlotinib multi-line therapy
- efficacy and safety poor performance status
- efficacy and safety combined immunotherapy
- efficacy and safety antiangiogenic therapy
- efficacy and safety immune checkpoint inhibitors
- safety of anlotinib treatment
- safety of anlotinib subgroup analysis
- safety of anlotinib network meta analysis
- efficacy and safety single agent chemotherapy